Merrimack Announces Major Corporate Restructuring
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St futures rise on Mideast deal optimism; SpaceX debut in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil falls to near two-month lows as Trump calls off threatened strikes on Iran
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
BTIG Affirms Merrimack Pharma (MACK) at 'Neutral' Amid Restructuring Plans
October 4, 2016 10:30 AM EDTBTIG affirms Merrimack Pharma (Nasdaq: MACK) with a Neutral rating following news that the company is undertaking a corporate restructuring.
BTIG commented late Monday, MACK announced a major corporate restructuring that cuts headcount by 22% and reduces $200M+ in expected expenses over the... More
